{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:30:19Z","timestamp":1786512619252,"version":"build-2736575974"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01225-2","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:06:32Z","timestamp":1779433592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of Aurora B induces senescence and potentiates immunotherapy in hepatocellular carcinoma"],"prefix":"10.1007","volume":"49","author":[{"given":"Shanshan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chune","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xifu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1225_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74, 229\u2013263 (2024)","journal-title":"Cancer J. Clin."},{"key":"1225_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"C. Yang, H. Zhang, L. Zhang, A.X. Zhu, R. Bernards, W. Qin et al., Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Reviews Gastroenterol. Hepatol. 20, 203\u2013222 (2023)","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"key":"1225_CR3","first-page":"1","volume":"17","author":"S Bruno","year":"2024","unstructured":"S. Bruno, A. Roberta, T. Luca, C. Luigi Eduardo, C. Alessandro, T. Giuseppe et al., Mechanism, Potential, and Concerns of Immunotherapy for Hepatocellular Carcinoma and Liver Transplantation. Curr. Mol. Pharmacol. 17, 1\u201313 (2024)","journal-title":"Curr. Mol. Pharmacol."},{"key":"1225_CR4","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1002\/wsbm.1640","volume":"16","author":"M Ren","year":"2024","unstructured":"M. Ren, C. Lu, M. Zhou, X. Jiang, X. Li, N. Liu, The intersection of virus infection and liver disease: A comprehensive review of pathogenesis, diagnosis, and treatment. WIREs Mech. Disease. 16, e1640 (2024)","journal-title":"WIREs Mech. Disease"},{"key":"1225_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"M Llovet Josep","year":"2008","unstructured":"M. Llovet Josep, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.-F. Blanc et al., Sorafenib in Advanced Hepatocellular Carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008)","journal-title":"N. Engl. J. Med."},{"key":"1225_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"M. Kudo, R.S. Finn, S. Qin, K.-H. Han, K. Ikeda, F. Piscaglia et al., Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 391, 1163\u20131173 (2018)","journal-title":"Lancet"},{"key":"1225_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"S Finn Richard","year":"2020","unstructured":"S. Finn Richard, S. Qin, M. Ikeda, R. Galle Peter, M. Ducreux, T.-Y. Kim et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020)","journal-title":"N. Engl. J. Med."},{"key":"1225_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"A.-L. Cheng, S. Qin, M. Ikeda, P.R. Galle, M. Ducreux, T.-Y. Kim et al., Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022)","journal-title":"J. Hepatol."},{"key":"1225_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"X. Yang, C. Yang, S. Zhang, H. Geng, A.X. Zhu, R. Bernards et al., Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 42, 180\u2013197 (2024)","journal-title":"Cancer Cell."},{"key":"1225_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Z. Ren, J. Xu, Y. Bai, A. Xu, S. Cang, C. Du et al., Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 22, 977\u2013990 (2021)","journal-title":"Lancet Oncol."},{"key":"1225_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"B. Sangro, S.L. Chan, R.K. Kelley, G. Lau, M. Kudo, W. Sukeepaisarnjaroen et al., Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. 35, 448\u2013457 (2024)","journal-title":"Ann. Oncol."},{"key":"1225_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.21147\/j.issn.1000-9604.2024.02.06","volume":"36","author":"H Liu","year":"2024","unstructured":"H. Liu, C. Wang, R. Wang, H. Cao, Y. Cao, T. Huang et al., New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma. Chin. J. Cancer Res. 36, 167\u2013194 (2024)","journal-title":"Chin. J. Cancer Res."},{"key":"1225_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.21147\/j.issn.1000-9604.2024.02.07","volume":"36","author":"S Rashid","year":"2024","unstructured":"S. Rashid, Y. Sun, U. Ali Khan Saddozai, S. Hayyat, M.U. Munir, M.U. Akbar et al., Circulating tumor DNA and its role in detection, prognosis and therapeutics of hepatocellular carcinoma. Chin. J. Cancer Res. 36, 195\u2013214 (2024)","journal-title":"Chin. J. Cancer Res."},{"key":"1225_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jhep.2020.01.019","volume":"72","author":"M M\u00fcller","year":"2020","unstructured":"M. M\u00fcller, T.G. Bird, J.-C. Nault, The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J. Hepatol. 72, 990\u20131002 (2020)","journal-title":"J. Hepatol."},{"key":"1225_CR15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"R.D. Kim, D. Sarker, T. Meyer, T. Yau, T. Macarulla, J.-W. Park et al., First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discov. 9, 1696\u20131707 (2019)","journal-title":"Cancer Discov."},{"key":"1225_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10637-023-01335-w","volume":"41","author":"M Zhou","year":"2023","unstructured":"M. Zhou, S. Zhu, C. Xu, B. Liu, J. Shen, A phase Ib\/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Investig. New Drugs. 41, 162\u2013167 (2023)","journal-title":"Investig. New Drugs"},{"key":"1225_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","volume":"19","author":"L Rimassa","year":"2018","unstructured":"L. Rimassa, E. Assenat, M. Peck-Radosavljevic, M. Pracht, V. Zagonel, P. Mathurin et al., Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 19, 682\u2013693 (2018)","journal-title":"Lancet Oncol."},{"key":"1225_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41575-021-00465-x","volume":"18","author":"C Wang","year":"2021","unstructured":"C. Wang, Y. Cao, C. Yang, R. Bernards, W. Qin, Exploring liver cancer biology through functional genetic screens. Nat. Reviews Gastroenterol. Hepatol. 18, 690\u2013704 (2021)","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"key":"1225_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41586-025-08585-z","volume":"639","author":"M M\u00fcller","year":"2025","unstructured":"M. M\u00fcller, S. May, H. Hall, T.J. Kendall, L. McGarry, L. Blukacz et al., Human-correlated genetic models identify precision therapy for liver cancer. Nature. 639, 754\u2013764 (2025)","journal-title":"Nature"},{"key":"1225_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41421-022-00425-y","volume":"8","author":"X Ma","year":"2022","unstructured":"X. Ma, S. Wu, B. Li, Q. Zhang, J. Zhang, W. Liu et al., EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma. Cell. Discovery. 8, 82 (2022)","journal-title":"Cell. Discovery"},{"key":"1225_CR21","doi-asserted-by":"crossref","unstructured":"J. Wang, L. Liao, B. Miao, B. Yang, B. Li, X. Ma et al., Deciphering the role of the MALT1\u2013RC3H1 axis in regulating GPX4 protein stability. Proceedings of the National Academy of Sciences. 2025;122:e2419625121","DOI":"10.1073\/pnas.2419625121"},{"key":"1225_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","volume":"134","author":"V Krizhanovsky","year":"2008","unstructured":"V. Krizhanovsky, M. Yon, R.A. Dickins, S. Hearn, J. Simon, C. Miething et al., Senescence of Activated Stellate Cells Limits Liver Fibrosis. Cell. 134, 657\u2013667 (2008)","journal-title":"Cell"},{"key":"1225_CR23","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1038\/s41467-024-46835-2","volume":"15","author":"CFA Ramirez","year":"2024","unstructured":"C.F.A. Ramirez, D. Taranto, M. Ando-Kuri, de M.H.P. Groot, E. Tsouri, Z. Huang et al., Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma. Nat. Commun. 15, 2581 (2024)","journal-title":"Nat. Commun."},{"key":"1225_CR24","doi-asserted-by":"crossref","unstructured":"Y. Shi, Z. Peng, Z. Pan, J. Duan, Z. Wang, Q. Guan et al., ST6GAL1-mediated sialylation inhibits the antitumor immune response in colorectal cancer. Cell. Oncol. (Dordr) 2025","DOI":"10.1007\/s13402-025-01118-w"},{"key":"1225_CR25","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3748\/wjg.v18.i27.3527","volume":"18","author":"W Mok","year":"2012","unstructured":"W. Mok, S. Wasser, T. Tan, S. Lim, Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J. Gastroenterol. 18, 3527\u20133536 (2012)","journal-title":"World J. Gastroenterol."},{"key":"1225_CR26","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1038\/s41467-018-05429-5","volume":"9","author":"G de C\u00e1rcer","year":"2018","unstructured":"de G. C\u00e1rcer, S.V. Venkateswaran, L. Salgueiro, El A. Bakkali, K. Somogyi, K. Rowald et al., Plk1 overexpression induces chromosomal instability and suppresses tumor development. Nat. Commun. 9, 3012 (2018)","journal-title":"Nat. Commun."},{"key":"1225_CR27","doi-asserted-by":"crossref","unstructured":"P. Dietrich, K. Freese, A. Mahli, W.E. Thasler, C. Hellerbrand, A.K. Bosserhoff, combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic dual-hit option. Oncotarget. 9, (2017)","DOI":"10.18632\/oncotarget.23188"},{"key":"1225_CR28","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.7150\/thno.25487","volume":"8","author":"CX Wu","year":"2018","unstructured":"C.X. Wu, X.Q. Wang, S.H. Chok, K. Man, S.H.Y. Tsang, A.C.Y. Chan et al., Blocking CDK1\/PDK1\/\u03b2-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 8, 3737\u20133750 (2018)","journal-title":"Theranostics"},{"key":"1225_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ebiom.2017.04.014","volume":"19","author":"J Cai","year":"2017","unstructured":"J. Cai, B. Li, Y. Zhu, X. Fang, M. Zhu, M. Wang et al., Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine. 19, 18\u201330 (2017)","journal-title":"EBioMedicine"},{"key":"1225_CR30","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1038\/s41467-022-29960-8","volume":"13","author":"CKY Ng","year":"2022","unstructured":"C.K.Y. Ng, E. Dazert, T. Boldanova, M. Coto-Llerena, S. Nuciforo, C. Ercan et al., Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages. Nat. Commun. 13, 2436 (2022)","journal-title":"Nat. Commun."},{"key":"1225_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41420-020-00393-w","volume":"7","author":"AK Shaalan","year":"2021","unstructured":"A.K. Shaalan, T.H.N. Teshima, A.S. Tucker, G.B. Proctor, Inhibition of Aurora Kinase B activity disrupts development and differentiation of salivary glands. Cell. Death Discovery. 7, 16 (2021)","journal-title":"Cell. Death Discovery"},{"key":"1225_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cell.2008.12.020","volume":"136","author":"P Steigemann","year":"2009","unstructured":"P. Steigemann, C. Wurzenberger, M.H.A. Schmitz, M. Held, J. Guizetti, S. Maar et al., Aurora B-Mediated Abscission Checkpoint Protects against Tetraploidization. Cell. 136, 473\u2013484 (2009)","journal-title":"Cell"},{"key":"1225_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"L. Wang, L. Lankhorst, R. Bernards, Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer. 22, 340\u2013355 (2022)","journal-title":"Nat. Rev. Cancer"},{"key":"1225_CR34","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","volume":"25","author":"B Wang","year":"2024","unstructured":"B. Wang, J. Han, J.H. Elisseeff, M. Demaria, The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell. Biol. 25, 958\u2013978 (2024)","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"1225_CR35","doi-asserted-by":"crossref","unstructured":"G.P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National Academy of Sciences. 1995;92:9363-7","DOI":"10.1073\/pnas.92.20.9363"},{"key":"1225_CR36","doi-asserted-by":"crossref","unstructured":"M. Narita, M. Narita, V. Krizhanovsky, S. Nu\u00f1ez, A. Chicas, S.A. Hearn et al., A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell. 2006;126:503\u2009\u2013\u200914","DOI":"10.1016\/j.cell.2006.05.052"},{"key":"1225_CR37","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1909","volume":"11","author":"F Rodier","year":"2009","unstructured":"F. Rodier, J.-P. Copp\u00e9, C.K. Patil, W.A.M. Hoeijmakers, D.P. Mu\u00f1oz, S.R. Raza et al., Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973\u2013979 (2009)","journal-title":"Nat. Cell Biol."},{"key":"1225_CR38","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrm2233","volume":"8","author":"J Campisi","year":"2007","unstructured":"J. Campisi, d\u2019Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729\u2013740 (2007)","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1225_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0092-8674(03)00401-X","volume":"113","author":"M Narita","year":"2003","unstructured":"M. Narita, S. Nu\u00f1ez, E. Heard, M. Narita, A.W. Lin, S.A. Hearn et al., Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular Senescence. Cell. 113, 703\u2013716 (2003)","journal-title":"Cell"},{"key":"1225_CR40","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1182\/blood.V114.22.2080.2080","volume":"114","author":"B Lowenberg","year":"2009","unstructured":"B. Lowenberg, P. Rousselot, G. Martinelli, A. Goudie, P. Stockman, H. Kantarjian, Phase I\/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia. Blood. 114, 2080 (2009)","journal-title":"Blood"},{"key":"1225_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdq344","volume":"22","author":"DS Boss","year":"2011","unstructured":"D.S. Boss, P.O. Witteveen, van der J. Sar, M.P. Lolkema, E.E. Voest, P.K. Stockman et al., Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann. Oncol. 22, 431\u2013437 (2011)","journal-title":"Ann. Oncol."},{"key":"1225_CR42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/2159-8290.CD-22-0528","volume":"13","author":"H-A Chen","year":"2023","unstructured":"H.-A. Chen, Y.-J. Ho, R. Mezzadra, J.M. Adrover, R. Smolkin, C. Zhu et al., Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity. Cancer Discov. 13, 432\u2013453 (2023)","journal-title":"Cancer Discov."},{"key":"1225_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2159-8290.CD-22-0523","volume":"13","author":"I Marin","year":"2023","unstructured":"I. Marin, O. Boix, A. Garcia-Garijo, I. Sirois, A. Caballe, E. Zarzuela et al., Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity. Cancer Discov. 13, 410\u2013431 (2023)","journal-title":"Cancer Discov."},{"key":"1225_CR44","doi-asserted-by":"publisher","first-page":"e110597","DOI":"10.15252\/embj.2022110597","volume":"42","author":"X Wang","year":"2023","unstructured":"X. Wang, H. Zhang, Y. Wang, L. Bramasole, K. Guo, F. Mourtada et al., DNA sensing via the cGAS\/STING pathway activates the immunoproteasome and adaptive T-cell immunity. EMBO J. 42, e110597 (2023)","journal-title":"EMBO J."},{"key":"1225_CR45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1046\/j.1440-1746.2002.02837.x","volume":"17","author":"M Matsui","year":"2002","unstructured":"M. Matsui, S. Machida, T. Itani-Yohda, T. Akatsuka, Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-\u03b3. J. Gastroenterol. Hepatol. 17, 897\u2013907 (2002)","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1225_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","volume":"109","author":"DA Ferrington","year":"2012","unstructured":"D.A. Ferrington, D.S. Gregerson, Immunoproteasomes: structure, function, and antigen presentation. Prog Mol. Biol. Transl Sci. 109, 75\u2013112 (2012)","journal-title":"Prog Mol. Biol. Transl Sci."},{"key":"1225_CR47","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s13402-024-00979-x","volume":"47","author":"S Zhang","year":"2024","unstructured":"S. Zhang, L. Ren, W. Li, Y. Zhang, Y. Yang, H. Yang et al., Interferon Gamma Inducible Protein 30: from biological functions to potential therapeutic target in cancers. Cell. Oncol. 47, 1593\u20131605 (2024)","journal-title":"Cell. Oncol."},{"key":"1225_CR48","doi-asserted-by":"crossref","unstructured":"V. Gorgoulis, P.D. Adams, A. Alimonti, D.C. Bennett, O. Bischof, C. Bishop et al., Cellular senescence: defining a path forward. Cell. 2019;179:813\u2009\u2013\u200927","DOI":"10.1016\/j.cell.2019.10.005"},{"key":"1225_CR49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00262-025-04060-w","volume":"74","author":"P Engels","year":"2025","unstructured":"P. Engels, A. Szolek, S. H\u00f6rner, G.V. Syrigos, K. Hebbel, M. Schmidtke et al., Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence. Cancer Immunol. Immunother. 74, 207 (2025)","journal-title":"Cancer Immunol. Immunother."},{"key":"1225_CR50","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1038\/s41388-024-03142-w","volume":"43","author":"J Du","year":"2024","unstructured":"J. Du, D. Bai, C. Gu, J. Zhao, C. Zhou, Y. Wang et al., Sorafenib-mediated cleavage of p62 initiates cellular senescence as a mechanism to evade its anti-hepatocellular carcinoma efficacy. Oncogene. 43, 3003\u20133017 (2024)","journal-title":"Oncogene"},{"key":"1225_CR51","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41598-023-28436-z","volume":"13","author":"B Gao","year":"2023","unstructured":"B. Gao, Y. Wang, S. Lu, Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. Sci. Rep. 13, 1137 (2023)","journal-title":"Sci. Rep."},{"key":"1225_CR52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12935-024-03351-z","volume":"24","author":"X Cai","year":"2024","unstructured":"X. Cai, G. Yin, S. Chen, F. Tacke, A. Guillot, H. Liu, CDK4\/6 inhibition enhances T-cell immunotherapy on hepatocellular carcinoma cells by rejuvenating immunogenicity. Cancer Cell Int. 24, 215 (2024)","journal-title":"Cancer Cell Int."},{"key":"1225_CR53","doi-asserted-by":"crossref","unstructured":"M. Colucci, M. Sarill, M. Maddalena, A. Valdata, M. Troiani, M. Massarotti et al., Senescence in cancer. Cancer Cell. 2025","DOI":"10.1016\/j.ccell.2025.05.015"},{"key":"1225_CR54","doi-asserted-by":"publisher","first-page":"212","DOI":"10.21147\/j.issn.1000-9604.2025.02.08","volume":"37","author":"H Chen","year":"2025","unstructured":"H. Chen, Z. Xiao, Z. Lu, N. Xu, Q. Wei, X. Xu, Targeted activation of junctional adhesion molecule-like protein+ CD8\u2009+\u2009T cells enhances immunotherapy in hepatocellular carcinoma. Chin. J. Cancer Res. 37, 212\u2013226 (2025)","journal-title":"Chin. J. Cancer Res."},{"key":"1225_CR55","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.redox.2024.103208","volume":"73","author":"D Li","year":"2024","unstructured":"D. Li, Q. Yu, R. Wu, Z. Tuo, J. Wang, L. Ye et al., Interactions between oxidative stress and senescence in cancer: Mechanisms, therapeutic implications, and future perspectives. Redox Biol. 73, 103208 (2024)","journal-title":"Redox Biol."},{"key":"1225_CR56","doi-asserted-by":"publisher","first-page":"e70021","DOI":"10.1111\/apm.70021","volume":"133","author":"C Wang","year":"2025","unstructured":"C. Wang, J. Liu, Y. Wu, C. Cai, Z. Chai, P. Jia et al., AURKB as a Therapeutic Target and Key Driver of Liver Cancer Growth and Metastasis. APMIS. 133, e70021 (2025)","journal-title":"APMIS"},{"key":"1225_CR57","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.21037\/atm-22-4798","volume":"10","author":"H Zhao","year":"2022","unstructured":"H. Zhao, Y. Wang, Z. Yang, W. Wei, Z. Cong, Y. Xie, High expression of aurora kinase B predicts poor prognosis in hepatocellular carcinoma after curative surgery and its effects on the tumor microenvironment. Annals Translational Med. 10, 1168 (2022)","journal-title":"Annals Translational Med."},{"key":"1225_CR58","doi-asserted-by":"crossref","unstructured":"J. Zhang, J. Ma, Y. Li, Y. An, W. Du, Q. Yang et al., Overexpression of Aurora Kinase B is correlated with diagnosis and poor prognosis in hepatocellular carcinoma. Int. J. Mol. Sci. 25, 2199 (2024)","DOI":"10.3390\/ijms25042199"},{"key":"1225_CR59","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/mc.23775","volume":"63","author":"G Zhu","year":"2024","unstructured":"G. Zhu, L. Luo, Y. He, Y. Xiao, Z. Cai, W. Tong et al., AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K\/AKT\/mTOR pathway. Mol. Carcinog. 63, 1814\u20131826 (2024)","journal-title":"Mol. Carcinog."},{"key":"1225_CR60","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/bjs.6011","volume":"95","author":"S Tanaka","year":"2008","unstructured":"S. Tanaka, S. Arii, M. Yasen, K. Mogushi, N.T. Su, C. Zhao et al., Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br. J. Surg. 95, 611\u2013619 (2008)","journal-title":"Br. J. Surg."},{"key":"1225_CR61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jhep.2009.10.013","volume":"52","author":"A Aihara","year":"2010","unstructured":"A. Aihara, S. Tanaka, M. Yasen, S. Matsumura, Y. Mitsunori, A. Murakata et al., The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J. Hepatol. 52, 63\u201371 (2010)","journal-title":"J. Hepatol."},{"key":"1225_CR62","first-page":"2284","volume":"55","author":"E Wang","year":"1995","unstructured":"E. Wang, Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res. 55, 2284\u20132292 (1995)","journal-title":"Cancer Res."},{"key":"1225_CR63","doi-asserted-by":"publisher","first-page":"0612","DOI":"10.34133\/research.0612","volume":"8","author":"J Wang","year":"2025","unstructured":"J. Wang, F. Shao, Q.X. Yu, L. Ye, D. Wusiman, R. Wu et al., The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies. Research. 8, 0612 (2025)","journal-title":"Research"},{"key":"1225_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"M. Milanovic, D.N.Y. Fan, D. Belenki, J.H.M. D\u00e4britz, Z. Zhao, Y. Yu et al., Senescence-associated reprogramming promotes cancer stemness. Nature. 553, 96\u2013100 (2018)","journal-title":"Nature"},{"key":"1225_CR65","first-page":"907","volume":"17","author":"S Xie","year":"2025","unstructured":"S. Xie, X. Luo, F. Hong, Y. Wei, Y. Hao, X. Xie et al., Towards Precision Aging Biology: Single-Cell Multi-Omics and Advanced AI-Driven Strategies. Aging Dis. 17, 907\u2013926 (2025)","journal-title":"Aging Dis."},{"key":"1225_CR66","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.15252\/embr.201439245","volume":"15","author":"BG Childs","year":"2014","unstructured":"B.G. Childs, D.J. Baker, J.L. Kirkland, J. Campisi, van J.M. Deursen, Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 15, 1139\u20131153 (2014)","journal-title":"EMBO Rep."},{"key":"1225_CR67","doi-asserted-by":"publisher","first-page":"11190","DOI":"10.1038\/ncomms11190","volume":"7","author":"R Yosef","year":"2016","unstructured":"R. Yosef, N. Pilpel, R. Tokarsky-Amiel, A. Biran, Y. Ovadya, S. Cohen et al., Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016)","journal-title":"Nat. Commun."},{"key":"1225_CR68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"J. Chang, Y. Wang, L. Shao, R.-M. Laberge, M. Demaria, J. Campisi et al., Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78\u201383 (2016)","journal-title":"Nat. Med."},{"key":"1225_CR69","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nchembio.1246","volume":"9","author":"G Lessene","year":"2013","unstructured":"G. Lessene, P.E. Czabotar, B.E. Sleebs, K. Zobel, K.N. Lowes, J.M. Adams et al., Structure-guided design of a selective BCL-XL inhibitor. Nat. Chem. Biol. 9, 390\u2013397 (2013)","journal-title":"Nat. Chem. Biol."},{"key":"1225_CR70","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1038\/s41467-022-35657-9","volume":"13","author":"J Kohli","year":"2022","unstructured":"J. Kohli, C. Ge, E. Fitsiou, M. Doepner, S.M. Brandenburg, W.J. Faller et al., Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression. Nat. Commun. 13, 7923 (2022)","journal-title":"Nat. Commun."},{"key":"1225_CR71","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"A.J. Souers, J.D. Leverson, E.R. Boghaert, S.L. Ackler, N.D. Catron, J. Chen et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013)","journal-title":"Nat. Med."},{"key":"1225_CR72","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s13402-024-01018-5","volume":"48","author":"K Czajkowski","year":"2025","unstructured":"K. Czajkowski, M. Herbet, M. Murias, I. Piatkowska-Chmiel, Senolytics: charting a new course or enhancing existing anti-tumor therapies? Cell. Oncol. 48, 351\u2013371 (2025)","journal-title":"Cell. Oncol."},{"key":"1225_CR73","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2024.01.025","volume":"166","author":"H Wang","year":"2024","unstructured":"H. Wang, S. Yuan, Q. Zheng, S. Zhang, Q. Zhang, S. Ji et al., Dual Inhibition of CDK4\/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs. Gastroenterology. 166, 1130\u20131144 (2024). e8","journal-title":"Gastroenterology"},{"key":"1225_CR74","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ccell.2016.09.003","volume":"30","author":"T Eggert","year":"2016","unstructured":"T. Eggert, K. Wolter, J. Ji, C. Ma, T. Yevsa, S. Klotz et al., Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell. 30, 533\u2013547 (2016)","journal-title":"Cancer Cell."},{"key":"1225_CR75","doi-asserted-by":"publisher","first-page":"eadp7022","DOI":"10.1126\/sciadv.adp7022","volume":"10","author":"Z Wang","year":"2024","unstructured":"Z. Wang, Y. Chen, H. Fang, K. Xiao, Z. Wu, X. Xie et al., Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals. Sci. Adv. 10, eadp7022 (2024)","journal-title":"Sci. Adv."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01225-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:03:17Z","timestamp":1786510997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01225-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01225-2","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The corresponding author is an editor of this journal and was not involved in the editorial handling of this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"107"}}